Use of interleukin-10 in adoptive immunotherapy of cancer

Details Use of interleukin-10 in adoptive immunotherapy of cancer Use of interleukin-10 in adoptive immunotherapy of cancer

1994-07-05

1998-07-07

Sayala, Chhaya D.

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

424 851, 530351, A61K 4505

Patent

active

057764514

ABSTRACT:
A method is provided for using interleukin-10 in adoptive immunotherapy of cancer. A population of tumor-infiltrating lymphocytes (TILs) are expanded in culture in the presence of interleukin-2 (IL-2) and interleukin-10 (IL-10). After administration of the TILs to a patient, effective amounts of both IL-2 and IL-10 are administered to enhance the tumor cell cytoxicity of the TILs and to reduce side effects caused by IL-2-induced cytokine production in the TILs and other cells of the patient.

REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 4877561 (1989-10-01), Iga et al.
patent: 4962091 (1990-10-01), Eppstein et al.
Cross et al., Infection and Immunity, pp. 2741-2747 vol. 61 (7), Jul. 1993.
Jain, Scientific American, Jul. 1994, pp. 58-65.
Curti, Critical Reviews in Oncology/Hematology, vol. 14, pp. 29-39, 1993.
Natavson et al., Annals of Int. Medicine, vol. 129 (9), pp. 771-783, May 1994.
Konrad, Michael, "Biological Barriers to Protein Delivery," ed. Audus et al., Plenum Press, NY, Chap 14, 1993.
Wedner, Basic & Clinical Immunology, Chap 34, Appleton & Lange, 7th Edition, Eds Stites et al., 1991.
Osband et al., Immunology Today, vol. 11(6), pp. 193-195, 1990.
Mier et al., J. Clin. Immunol., vol. 8(6), pp. 426-436, 1988.
Martin et al., Cancer Rs., vol. 46, pp. 2189-2192, Apr. 1986.
Whicher et al. (1990) Clin. Chem. 36(7):1269-1281.
Rosenberg et al. (1986) Science 233:1318-1321.
Fiorentino et al. (1989, Dec.) J. Exp. Med. 170:2081-2095.
Ronald B. Herberman, "Multiple Functions of Natural Killer Cells, Including Immunoregulation as Well as Resistance to Tumor Growth," Concepts Immunopathol., 1:96-132, 1985.
Di-Hwei Hsu, et al., "Differential Effects of IL-4 and IL-10 on IL-2-induced IFN-.gamma. Synthesis and Lymphokine-activated Killer Activity," Int. Immunol., 4:563-569, 1992.
Attan Kasid, et al., "Induction of Endogenous Cytokine-mRNA in Circulating Peripheral Blood Mononuclear Cells by IL-2 Administration to Cancer Patients," J. Immunol., 143:736-739, Jul. 1989.
Amy H. Kragel, et al., "Pathologic Findings Associated With Interleukin-2-Based Immunotherapy for Cancer: A Postmortem Study of 19 Patients," Human Pathology, 21:493-502, May 1990.
Ian A. MacNeil, et al., "IL-10, a Novel Growth Cofactor for Mature and Immature T Cells," J. Immunol., 145:4167-4173, Dec. 1990.
Steven A. Rosenberg, "Adoptive Immunotherapy for Cancer," Scientific American, pp. 62-68, May 1990.
Steven A. Rosenberg, et al., "Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma," NE J. Med., 319:1676-1680, Dec. 1988.
Robert I. Tepper, et al., "Murine Interleukin-4 Displays Potent Anti-Tumor Activity In Vivo," Cell, 57:503-512, May 1989.
Suzanne L. Topalian, et al., "Expansion of Human Tumor Infiltrating Lymphocytes for Use in Immunotherapy Trials," J. Immunol. Methods, 102:127-141, 1987.

Affiliated with

Also associated with

Rating

Use of interleukin-10 in adoptive immunotherapy of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of interleukin-10 in adoptive immunotherapy of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of interleukin-10 in adoptive immunotherapy of cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1202532